<DOC>
	<DOCNO>NCT02622386</DOCNO>
	<brief_summary>The purpose study determine anti-inflammatory effect high-dose riboflavin supplementation chronic plaque psoriasis . Psoriasis common chronic skin disorder affect 4 million people . There cure psoriasis treatment direct control patient ' symptom . Amongst patient skin disease , significant interest use complementary alternative medicine vitamins treat disease . Previous human case report suggest riboflavin , commonly know Vitamin B2 , clinically effective treatment psoriasis ; however , conclusive . More recent human trial show 400 mg daily oral riboflavin safe well-tolerated medication administer human . For purpose study , riboflavin use investigational drug .</brief_summary>
	<brief_title>The Effect Riboflavin Moderate Severe Plaque Type Psoriasis</brief_title>
	<detailed_description>The purpose investigation determine anti-inflammatory effect high-dose riboflavin supplementation chronic plaque psoriasis . Up fifty volunteer chronic plaque psoriasis recruit double-blind , placebo-controlled 28 week prospective study cross-over intervention control group 12 week time mark . There 4 week washout period subject crossover . Riboflavin dose 400 mg mouth daily versus placebo . Throughout study investigator perform clinical laboratory assessment measure response .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Riboflavin</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>18 year age older Good general health Willingness ability follow protocol Signed Informed Consent Form , write witness . Stable moderate severe chronic plaque psoriasis involve 8 % great total body surface area ( TBSA ) . If subject woman childbearing potential , must negative pregnancy test screen agree use medically acceptable form contraception screen throughout study . Used topical steroid strong moderate strength , vitamin A D analog preparation , anthralin within 14 day study drug initiation . Used systemic medication phototherapy within 28 day study drug initiation . Used biologic medication within 5 halflives study drug initiation ( determined halflife biologic medication ) . Prior concurrent use cyclophosphamide . Currently use sulfasalazine therapy . Known hypersensitivity riboflavin . Enrolled investigational device investigational drug trial ( ) receipt investigational agent ( ) within 28 day baseline visit . Presence severe comorbidities , diabetes mellitus require insulin ; CHF severity myocardial infarction cerebrovascular accident transient ischemic attack within 3 month screen visit ; unstable angina pectoris , uncontrolled hypertension [ sit systolic BP &lt; 80 mm Hg &gt; 160 diastolic BP &gt; 100 mm Hg ] , oxygendependent severe pulmonary disease , history cancer within 5 year [ resect cutaneous basal squamous cell carcinoma skin situ cervical cancer ] . Any follow hematologic abnormality , confirm repeat test least 1 week apart : 1 . White blood count &lt; 3,000/µL &gt; 14,000/µL 2 . Lymphocyte count &lt; 1,000/µL 3 . Neutrophil count &lt; 1,5000/µL 4 . Platelet count &lt; 150,000/µL 5 . Hemoglobin &lt; 10 g/dL Liver function test ( aspartate aminotransferase [ AST ] , alanine aminotransferase [ ALT ] alkaline phosphatase [ AlkP ] ) result great equal 2 time upper limit normal ( ULN ) . Serum creatinine ≥ 2x ULN . Known HIVpositive status know history immunesuppressing disease . Any current past history psychiatric disease would interfere ability comply study protocol give informed consent . Had grade 3 4 adverse event infection within 28 day screen , screen visit drug initiation . Evidence skin condition psoriasis would interfere evaluation effect study medication psoriasis . Presence condition circumstance judge patient 's physician , investigator , medically qualify study staff render clinical trial detrimental otherwise unsuitable patient 's participation . A history noncompliance therapy . Females pregnant , lactating , plan pregnancy study period , unwilling use FDAapproved method birth control . A history keloid excessive scar formation A history allergic reaction local anesthetic , include lidocaine epinephrine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Psoriasis</keyword>
</DOC>